Product Center
The first trivalent subunit influenza vaccine for the entire population in China has been approved for sale, filling the gap in high-end influenza vaccines in China
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-01-30
- Views:
(Summary description)Recently, various infectious disease outbreaks have ravaged the world. Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") has officially approved the launch of its independently developed influenza virus subunit vaccine ( HRK-X® 3) by the National Medical Products Administration (NMPA)! We will continue to assist in global epidemic prevention and control!
The first trivalent subunit influenza vaccine for the entire population in China has been approved for sale, filling the gap in high-end influenza vaccines in China
(Summary description)Recently, various infectious disease outbreaks have ravaged the world. Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") has officially approved the launch of its independently developed influenza virus subunit vaccine ( HRK-X® 3) by the National Medical Products Administration (NMPA)! We will continue to assist in global epidemic prevention and control!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-01-30 09:08
- Views:
Recently, various infectious disease outbreaks have ravaged the world. Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") has officially approved the launch of its independently developed influenza virus subunit vaccine ( HRK-X® 3) by the National Medical Products Administration (NMPA)! We will continue to assist in global epidemic prevention and control!
This is currently the first and only approved trivalent influenza virus subunit vaccine for the entire population aged 6 months and above in China. This approval marks Ab&B Bio's successful establishment of a "quadrivalent+trivalent" high-end influenza vaccine product dual defense line, further consolidating the company's leading position in the field of subunit vaccines and injecting strong "Ab&B Bio's power" into the multidimensional infectious disease prevention and control industry in China and even globally.
Influenza is a major public health challenge that threatens public health, and vaccination is the most economical and effective way to prevent influenza. However, for a long time, the influenza vaccine for infants and young children (6-35 months old) has faced the pain point of "halving the dose and potentially limited protection". Clinical data shows that full dose vaccination can provide stronger immune protection for infants and young children, and has good safety. Phase III clinical data shows that local adverse reactions are lower in the split vaccine group compared to the control group.
In 2024, the World Health Organization (WHO) stated that the B/Yamagata strain of influenza virus has not been detected globally since March 2020, and recommended that future influenza vaccines no longer include this component. Ab&B Bio actively responds to global scientific consensus and quickly promotes the registration and listing of trivalent influenza virus subunit vaccines. HRK-X® 3 accurately covers the three major strains of H1N1, H3N2, and Victoria B currently prevalent, providing the public with more precise and pure protection options that are in line with the latest international trends.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
